Life science platform company Vion Biosciences has acquired Ansh Labs, a Houston-based biotechnology firm developing immunoassay kits and reagents used in research and clinical diagnostics.
The acquisition enhances Vion Biosciences’ ability to support the diagnostic market by providing essential tools for clinical research in various clinical diagnostic areas.
The financial terms of the deal were not disclosed.
Vion Biosciences specialises in speciality materials for research, diagnostics, and drug discovery.
In addition, the transaction represents Vion Biosciences’ third investment under the backing of private equity firm Iron Path Capital and its second acquisition in August.
Recently, the firm acquired Echelon Biosciences, a supplier of critical materials, notably lipid-based excipients. In August 2023, the life science platform company acquired lab chemicals and chemical contract manufacturing solutions provider Aldon.
Vion’s acquisition of Ansh Labs brings contract development and custom manufacturing services for immunoassays and speciality reagents into its offerings.
This expands the portfolio for diagnostics and biotech research of the life science platform company.
The addition complements the firm’s existing suite of speciality products and services.
Additionally, Ansh Labs’ expertise in monoclonal antibody development enhances its ability to produce and screen a broad range of antibodies, optimising pairs for more effective immunoassays.
This capability enables the creation of specific assays for detecting clinically significant biomarkers and accelerates drug discovery processes.
Ansh’s products are utilised across academic research, clinical laboratories, and pharmaceutical development, with applications in studies on fertility, pregnancy, bone metabolism, obesity, and cancer.
Vion Biosciences CEO Mark Thornton said: “Ansh’s commitment to innovation and quality is a natural fit for Vion, and our acquisition of Ansh Labs coupled with our two previous acquisitions collectively give Vion the combined resources, capabilities, core competencies, and of course the talents of all Vion’s employees to meet the goals of our customers now and into the future.”
The latest acquisition, coupled with other two deals expanded Vion Biosciences’ team to nearly 100 employees.
It also enhances the company’s capabilities, including GMP manufacturing for in-vitro diagnostics (IVD) and ISO 13485 certification.
Vion now operates from three locations across North America and extends its global reach to Europe and Asia.
